Health Catalyst Q1 2024 Adj EPS $0.05 Beats $0.03 Estimate, Sales $74.723M Miss $74.802M Estimate
Portfolio Pulse from Benzinga Newsdesk
Health Catalyst (HCAT) reported Q1 2024 adjusted EPS of $0.05, surpassing the $0.03 estimate, with sales of $74.723M slightly missing the $74.802M estimate. Year-over-year, sales increased by 1.16% from $73.868M.
May 09, 2024 | 8:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Health Catalyst reported a Q1 2024 EPS of $0.05, beating estimates, but sales of $74.723M slightly missed expectations. Sales grew 1.16% YOY.
The positive earnings beat by Health Catalyst is likely to be viewed favorably by investors, indicating operational efficiency and profitability. However, the slight miss on sales estimates could temper enthusiasm, suggesting a balanced short-term impact on the stock price. The year-over-year sales growth indicates a positive trend in revenue, supporting a neutral to slightly positive outlook.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100